Answers are grounded in this paper and cite their sources.
Patients express preferences for bispecific antibodies, highlighting the importance of treatment attributes in managing relapse/refractory diffuse large B-cell lymphoma.
Background Two recently approved bispecific antibodies (bsAbs) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) include epcoritamab (subcutaneous, SC) administered until progression (TTP), and glofitamab (intravenous, IV) for fixed duration (FTD). Understanding patient preferences for treatment attributes is critical for patient-centered decision-making.
No takes yet. Share an insight, caveat, or question.
Mulvey et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: